Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 19/20 | 0.58 |
| ▸ | KLK1 | P06870 | 5/20 | 0.58 |
| ▸ | KLKB1 | P03952 | 8/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17477793 | 1.00 | F11 (0.58) | F11KLK1KLKB1MEN1MAPT | |
| SCHEMBL17477791 | 1.00 | F11 (0.58) | F11KLK1KLKB1MEN1MAPT | |
| SCHEMBL17480784 | 0.95 | F11 (0.52) | F11KLK1KLKB1 | |
| SCHEMBL17480787 | 0.95 | F11 (0.52) | F11KLK1KLKB1 | |
| SCHEMBL20979584 | 0.91 | F11 (0.49) | F11KLK1KLKB1MEN1MAPT | |
| SCHEMBL20979725 | 0.91 | F11 (0.49) | F11KLK1KLKB1MEN1MAPT | |
| SCHEMBL17481099 | 0.90 | F11 (0.48) | F11KLK1KLKB1MEN1MAPT | |
| SCHEMBL20979650 | 0.86 | F11 (0.43) | F11KLK1MEN1MAPTCRHBP | |
| SCHEMBL17480788 | 0.86 | F11 (0.45) | F11KLK1KLKB1MEN1MAPT | |
| SCHEMBL17481104 | 0.83 | F11 (0.42) | F11KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180327-B1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME (US) | 2019-05-08 | — | — | EP | disclosed |
| US-10011585-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170240523-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-08-24 | — | — | US | disclosed |
| EP-3180327-A1 | FACTOR XIa INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-06-21 | — | — | EP | disclosed |
| WO-2016018701-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-02-04 | — | — | WO | disclosed |
| WO-2016018701-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240523-A1 | FACTOR XIa INHIBITORS | F11, SERPINC1, TFPI | F11 1/4885KLK1 24/4885KLKB1 14/4885 |
| US-10011585-B2 | Factor XIa inhibitors | F11, SERPINC1, TFPI | F11 1/4885KLK1 24/4885KLKB1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.